ASTANA, Kazakhstan, Dec. 15, 2023 /PRNewswire/ — Yesterday, the VII meeting of the Astana Club dedicated to the topic "A new formula for peace: the world on the verge of transformation" was held in Kazakhstan’s capital, Astana.

ASTANA CLUB 2023

The strategic stalemate in Ukraine was the key topic all the discussions were centered around.

The First President of Kazakhstan Nursultan Nazarbayev noted during his speech at the Club meeting that he was once a direct participant in the process of conflict resolution in Ukraine.

"I put a lot of effort into organizing the Minsk agreements meeting at the height of the Ukrainian crisis in 2014. Back then, it was for the first time possible to organize a face-to-face dialogue between the leaders of Russia and Ukraine.

The Minsk agreements opened the way to negotiations and compromise. Unfortunately, it didn’t work out. We know the result now", Nazarbayev stated.

In his opinion, the reality on the battlefield today is that a way out of the Ukrainian deadlock is possible only through negotiations.

"In my opinion this severe conflict in the center of Europe could be stopped only by great powers, the United States and Russia, inviting also other leaders to dialogue if there is a will and desire on their side. And of course, always considering the interests of Ukraine", he said.

The Club’s participants shared this vision about the current deadlock in war.

For instance, Charles Kupchan, Senior Fellow at the Council on Foreign Relations said: "We have a zugzwang on the battlefield, Russia has no success in 2023, and neither does Ukraine. We also see that it will be much more difficult for the U.S. to maintain support for Ukraine".

Considering China’s approach to this conflict, Senior colonel Zhou Bo, a prominent Chinese military expert from Tsinghua University, emphasized that Beijing should not be blamed for adopting its current position.

"The outbreak of World War III would have been predetermined, if only China supported Russia’s position. However, China is in favor of a peaceful settlement, and has made its own proposals", he said.

All participants, including former Prime minister of Spain José Luis Rodríguez Zapatero stated the importance of having a neutral platform for negotiations. Kazakhstan with its multi-vector foreign policy could become a perfect place for the resolution of the Ukrainian crisis.

Source : Astana Club: Nursultan Nazarbayev – Moscow and Washington need to hold direct talks to resolve the deadlock in Ukraine

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

BEIJING, Dec. 15, 2023 /PRNewswire/ — Recently, Wandong’s seven major series of products obtained the MDR certificate, following the completion of the first MDR certification for superconducting magnetic resonance.

So far, Wandong’s full range of X-ray, CT and MRI products have been completed the switching from CE MDD to CE MDR.

High standards define high reliability

CE certification, as a "visa" for products to enter the European market, is a mandatory requirement for product access in the EU market. The Medical Device (MDR) Regulation (EU) 2017/745 was issued in May 2017, compared with the MDD directive, the MDR regulation has stricter and more comprehensive requirements for medical devices, and the pre-market certification review is more difficult and the certification cycle is longer, and all those changes has raised the threshold for certification.

Wandong always follows high level of standard, and the full range of X-ray, CT and MRI products have been completed certification of CE MDR.

Established in China, Impacting the World

Wandong Medical, as a professional manufacturer in the medical imaging industry, always adheres to technology innovation, continuously improves its quality management, and is committed to launching high-quality, high-performance, reliable products for customers all over the world.

The MDR certification acts as a catalyst for Wandong to expand its coverage in the international market, accelerate the process of globalization, and contribute Chinese solutions to the health of people around the world.

Beijing Wandong Medical Technology Co.,Ltd has dedicated itself to the R&D, manufacture, sales and service of medical imaging equipment for nearly 70 years. In addition to a wide sales and service network all over China, our export destination covers more than 70 countries. With strict production and quality management, our MRI systems and major X-ray equipment are ISO/CE/FDA cleared. Over 8500 units of equipment are manufactured annually.

The company philosophy, "Precision and Vision", is our motivation to strive for advancement and innovation.

Source : Wandong Medical's full-line products obtain the MDR certification, facilitating its entry to the European market

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SeekIn to Grant Oncolnv the Rights to Represent SeekIn’s Comprehensive Range of Cancer Detection Tests in Twelve Countries to Provide Individuals with Accessible and Affordable Cancer Detection Tests

SHENZHEN, China, Dec. 15, 2023 /PRNewswire/ — SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, announced a strategic collaboration with Oncolnv, a fully-owned affiliate of Inspire2Live, to expand the global accessibility of their multiple cancer detection tests and bridge disparities in cancer care. Starting this December, SeekIn’s comprehensive range of cancer detection tests, namely OncoSeek, SeekInCare, SeekInCure and SeekInClarity will be distributed by Oncolnv in the following twelve countries: Belgium, Bulgaria, Costa Rica, Egypt, Ghana, Kenya, the Netherlands, Nigeria, Qatar, Singapore, Tanzania and UAE.

The agreement was formalized during the 2023 Inspire2Live Annual Congress held on November 29th and 30th in Amsterdam, the Netherlands. Representatives from 27 countries who are devoted to bringing the patient voice to the table joined this year’s congress on the theme of "If about us, not without us". SeekIn’s founder and CEO, Dr. Mao Mao, delivered an inspiring speech, shedding light on the company’s cutting-edge cancer detection tests, while emphasizing the importance of early detection and improved patient outcomes. The OncoSeek test focuses on screening nine common cancer types with seven protein tumor markers (PTMs) whereas SeekInCare, SeekInCure and SeekInClarity are designed for cancer early detection, recurrence monitoring and treatment monitoring respectively incorporating shallow whole genomic sequencing and PTMs. Participants at the Inspire2Live congress were given the opportunity to take an OncoSeek test.

Commenting on the significance of this collaboration, Dr. Mao Mao stated, "We are thrilled to join forces with Inspire2Live and Oncolnv, two patient-centric organizations committed to revolutionizing cancer detection and treatment. With their extensive network and dedication to the cause, we can better serve cancer patients globally, providing them with advanced detection technologies and empowering healthcare providers with the tools that they need to fight this devastating disease."

Inspire2Live’s founder, Mr. Peter Kapitein, expressed his excitement about the partnership, stating, "This collaboration aligns perfectly with our organization’s vision of a world where access to quality cancer care is universal. Together, we can make a real difference in the lives of countless patients around the globe." Oncolnv is at the forefront of clinical settings and pays considerable attention to cancer screening, early diagnosis and personalized monitoring with patient care at the core. By partnering with SeekIn, Oncolnv gains valuable access to comprehensive cancer detection solutions for diverse health care systems, helping to bridge global disparities in cancer care.

In addition, this collaboration opens doors to future research initiatives, creating opportunities for joint clinical trials, information exchange, and collaborative development of innovative cancer detection methodologies. By leveraging the expertise of both organizations, this collaborative effort aims to improve patient outcomes and increase survival rates.

As SeekIn expands its global footprint, its commitment to research, innovation, and patient-centric care remains unwavering. The collaboration between SeekIn and Oncolnv brings together the collective expertise and resources needed to address the global cancer burden comprehensively.

About SeekIn:

SeekIn Inc is a biotech company founded in early 2018 in Shenzhen, China, focusing on blood-based pan-cancer early detection utilizing next-generation sequencing and artificial intelligence. Since its creation, SeekIn has been committed to providing cutting-edge and cost-effective solutions for cancer early detection, postoperative recurrence monitoring, and treatment response evaluation. SeekIn also developed novel molecular tests for leukemia patients. Its cancer early detection technology has also successfully been applied to canines. With its proprietary technical advances, SeekIn has launched a number of research and clinical studies in collaboration with top-tier hospitals in China. SeekIn envisions that, by leading a new norm for cancer early detection, the clinical outcome of mid-/late-stage cancer patients can be reversed and the cancer mortality rate can be reduced by 15%. For more information about SeekIn’s cutting-edge technologies and products, visit www.seekincancer.com. 

About Inspire2Live:

Inspire2Live was founded in the Netherlands in 2010 and works globally with professional volunteers. Inspire2Live has initiated dozens of projects by simply bringing the right people together and supporting them to cooperate productively. Not just talking about cooperation but really working together and delivering concrete results and this is what distinguishes Inspire2Live from most other organizations. Inspire2Live is also supported by its ambassadors, including several Nobel prize winners.

Source : SeekIn and OncoInv Collaborate to Expand the Global Accessibility of Multiple Cancer Detection Tests and Bridge Global Disparities in Cancer Care

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

HONG KONG, Dec. 15, 2023 /PRNewswire/ — Akeso published two phase Ib clinical results of its innovative CD47 monoclonal antibody ligufalimab (AK117) in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) and treatment-naïve acute myeloid leukemia (AML) at the 65th American Society of Hematology (ASH) Annual Meeting.

HR-MDS

Anemia is a significant symptom of MDS, and effectively managing anemia and minimizing blood transfusion are crucial aspects of disease control. As of August 25, 2023, a total of 86 patients were evaluable for safety. Anemia (a primary adverse event associated with CD47 blocking antibodies) occurred in only 29.1% of the patients. Of 13 evaluable patients who initially required red blood cell (RBC) transfusions, 61.5% became independent of RBC transfusion.

Among 27 evaluable patients, the complete remission (CR) rate was 48.1% and the overall response rate (ORR) was 85.2%. When patients received≥3 cycles of treatment, the CR rate reached 52%; when patients received≥6 cycles of treatment, the CR rate reached 68.4%. AK117 combination therapy provides patients with rapid and significant remission. The median time to response (mTTR) was 0.97 months and the median time to CR (mTTCR) was 2.92 months.

AK117 is an IgG4 monoclonal antibody targeting CD47 without inducing hemagglutination effects. Therefore, AK117 does not require a lower ‘priming dose’ to prevent anemia. AK117 has emerged as a potential best-in-class therapy for MDS. In this study, AK117 in combination with AZA was well tolerated with low incidence of anemia and demonstrated promising efficacy in patients with newly diagnosed HR-MDS. AK117 is expected to be a superior treatment option for MDS patients worldwide.

Akeso has received FDA clearance for the Investigational New Drug (IND) application for AK117 in combination with azacitidine for the treatment of patients with newly diagnosed higher-risk MDS. This randomized, double-blind, global multi-center Phase II study is underway. Notably, Akeso is consistently advancing the development of AK117 as a therapeutic agent in combination with various agents such as PD-1/CTLA-4 and PD-1/VEGF bispecific antibodies, for the treatment of multiple hematologic malignancies and solid tumors.

AML

As of August 25, 2023, among 20 evaluable patients, the composite complete remission(CCR)  rate was 55%, with 50.0% of patients achieving CR.

The combination of AK117 and AZA exhibited a manageable safety profile with a low incidence of anemia, and demonstrated promising efficacy as a first-line treatment in AML patients who were unable to undergo intensive chemotherapy. Akeso is planning to conduct a randomized, open-label, phase II study to evaluate the safety and efficacy of AK117 in combination with venetoclax and AZA in patients with AML unfit for first-line intensive chemotherapy.

About Ligufalimab (AK117)

AK117, independently developed by Akeso, is a next-generation humanized lgG4 anti-CD47 antibody without hemagglutination effect. AK117 can bind to CD47 expressed on tumor cells and block the interaction between CD47 and SIRPα, in order to enhance the phagocytic activity of phagocytes on tumor cells, thereby inhibiting the growth of tumors.

Currently, several phase II clinical trials are underway to investigate the potential of AK117 in combination with azacitidine for hematological tumors, as well as AK117 alone or in combination with PD-1/CTLA-4 and PD-1/VEGF bispecific antibodies for various solid tumors. Preliminary studies have shown promising efficacy and safety profiles of AK117, with no observed dose-limiting toxicity events. Additionally, an international multicenter clinical study evaluating AK117 for the treatment of MDS has been initiated.

About Akeso, Inc.

Akeso (HKEX: 09926) is a commercial-stage biopharmaceutical company committed to discovering, developing, manufacturing, and commercializing innovative medicines that address significant medical needs globally. Since our inception, we have established a distinctive and integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the fundamental components, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode.

Akeso is actively developing a diverse pipeline of over 30 innovative assets in areas such as cancer, autoimmune disease, inflammation, metabolic disease, and other therapeutic fields. Among these, 19 assets have entered the clinical stage, with 3 innovative drugs already approved, 13 Phase III studies ongoing. Utilizing its proprietary Tetrabody technology, Akeso has successfully developed the first-in-class PD-1/CTLA-4 bispecific antibody drug for the market. Additionally, the company has five other innovative bispecific antibody drugs in the clinical stage, including ivonescimab (PD-1/VEGF), PD-1/LAG-3, TIGIT/TGF-Beta, PD-1/CD73, and claudin18.2/CD47 bispecific antibodies.

In June 2022, cadonilimab was approved by the NMPA and became the first commercialized bispecific IO drug globally. Another Akeso internally discovered and developed oncology product, penpulimab (a PD-1 antibody), was granted marketing approval in China in August 2021. In December 2022, Akeso entered into a collaboration and license agreement for up to US$5 billion with Summit Therapeutics to accelerate global development and commercialization of ivonescimab. In August, the NDA submission of ivonescimab was accepted by China’s NMPA with priority review. Akeso is listed on the Main Board of the Stock Exchange of Hong Kong Limited.

For more information, please visit https://www.akesobio.com/en/ and follow us on X (formerly Twitter) @AkesoInc

Source : Akeso Published Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-naïve Acute Myeloid Leukemia at ASH 2023

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

HANOI, Vietnam, Dec. 15, 2023 /PRNewswire/ — Recently, a Chinese company has added another example of propelling the energy transformation of Vietnam. The Power Construction Corporation of China (hereinafter referred to as POWERCHINA) and the Trungnam Group signed an EPC contract for the 916 MW wind power project cluster in Hanoi, Vietnam to conduct in-depth discussions on cooperation in the energy and electric power field. The agreement signifies a positive contribution to the adjustment of Vietnam’s energy structure and the reduction of carbon emissions.

China and Vietnam are linked by mountains and rivers, sharing common cultures, common ideals and a common destiny. On December 2th, the Vietnamese newspaper – The People, published an article signed by the General Secretary Xi Jinping, titled "Building a China-Vietnam Community of Shared Future with Strategic Significance and Opening a New Chapter of Joining Hands towards Modernization". The article points out that we adhere to the integration of benefits. Chinese companies have built the largest photovoltaic industry cluster overseas in Vietnam, and the photovoltaic and wind power stations invested and constructed have been making positive contributions to the energy transformation and development of Vietnam. Multiple waste-to-energy projects have been invested and built in places such as Hanoi and Can Tho.

POWERCHINA has been leveraging its advantages in the entire industry chain to build a large number of reputable and replicable clean energy projects in Vietnam. So far, 50 new energy projects such as onshore wind power, offshore wind power, and photovoltaics have been completed or under construction in Vietnam, with a total installed capacity of 5,540 megawatts, making POWERCHINA the largest electricity EPC enterprise in the Vietnamese market for five consecutive years. The new energy projects constructed can reduce carbon emissions by 7.5 million tons annually, while offering over 150,000 job opportunities in Vietnam.

PV Project in Dau Tieng, Vietnam

In Can Tho, Vietnam, 400 tons of household wastes are converted into electricity every day, providing approximately 60 million KWH of green electricity for the entire city. This waste-to-energy power generation project in Can Tho is constructed by POWERCHINA. Here, the team carries out in-depth quality management work to make the value of smoke emission particles far lower than Vietnam’s national standards and EU 2010 standards. It has been selected by the UN South-South Cooperation as an environmental sustainability and climate action urban innovation project, and is eligible for the typical green "Belt and Road" project at the Commemorative Summit Marking the 30th Anniversary of  ASEAN-China Dialogue Relations.

As a representative of Chinese enterprises in Vietnam, POWERCHINA adheres to project development as the driving force to gear up design and construction, equipment manufacturing, and power plant operation and maintenance businesses, building a high-quality localized business ecosystem, striving for the goal of "Building a China-Vietnam Community of Shared Future with Strategic Significance " through practical actions, making positive contributions to helping Vietnam achieve the "2050 carbon neutrality".

Source : Propelling the Building of a Community of Shared Future between China and Vietnam: A Chinese Company Signed a Contract for a 916 MW Wind Power Project in Vietnam

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

WILLEMSTAD, Curacao, Dec. 15, 2023 /PRNewswire/ — SlotGems, the online casino platform, is gearing up for a significant update with the impending launch of its refined welcome package and promotional offerings. Focused on delivering an improved gaming experience, SlotGems anticipates that their latest offerings will bring increased value and excitement to players.

In addition to these updates, SlotGems has also expanded its language support to cater to a global audience. Users can navigate the casino in English, French, German, Finnish, Norwegian, Spanish, Russian, Turkish and Chinese. By removing language barriers, the platform aims to provide a more inclusive and accessible environment to players from diverse backgrounds.

SlotGems remains committed to enhancing its users’ overall online casino experience with consistent updates. In the meantime, players are encouraged to visit Slotgems’ extensive library of slots and live dealer games.

Source : SLOTGEMS TO INTRODUCE NEW WELCOME AND PROMOTIONAL PACKAGE

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

HONG KONG, Dec. 15, 2023 /PRNewswire/ — The weather was gradually cooling down, which means that Hong Kong is entering the winter influenza season. Recently, there has been a significant increase in Mycoplasma pneumoniae infections, the surveillance data from the Centre for Health Protection (CHP) in the past four weeks (as of November 25) revealed that the parainfluenza viruses and adenovirus, with the latest positive percentage of 5.2 percent and 4.4 percent respectively and are on a rising trend. With bacteria and viruses floating in the air, many people have resumed wearing masks for protection when going out. In addition to surgical masks, the protective nasal spray can also create a physical barrier in the nasopharynx that blocks the attachment of airborne viruses.

BioSURE Pro Protective Nasal Spray is lightweight and convenient for travel

Infused with Lavender Fragrance for Comprehensive Nasal Coverage
BioSURE Pro Protective Nasal Spray is specially formulated with a lavender scent, making the spray more refreshing, and reducing the pungent scent caused by medicinal ingredients. The unique fragrance of lavender scent also helps people relax, which can provide a comfortable experience for consumers. It not only can keep the nasal cavity fresh, but also helps resist viral invasion.

To effectively defend against viruses, the spray needs to adhere accurately and persistently inside the nasal cavity to create a physical barrier. The plume application of BioSURE Pro Protective Nasal Spray has optimum coverage to the entire nasal cavity, blocking viral attachment to the nasopharynx for 6 hours instantly.

A Must-Have for Traveling with a unique patented ingredient blocking over 99% of various respiratory viruses
When traveling outside, there are significant environmental changes, the bacteria and viruses are hidden in the air. Being away from familiar surroundings, many people may not adapt to different environments in other countries. Combined with the absence of additional protections like surgical masks, it may have a decrease in resistance, leading to physical discomfort and a compromised travel experience.

BioSURE Pro Protective Nasal Spray is lightweight and convenient for travel. It occupies minimal space in luggage, and with just two sprays per nostril while using the nasal sprays, can provide instant protection for 6 hours. Whether for outdoor activities, travel, or work, it can be easily carried along, and protect against infection by respiratory viruses. The clinical trials have demonstrated that BioSURE Pro Protective Nasal Spray is free from harmful substances, can be reapplied every 6 hours for continued protection if needed and blocks common airborne viruses.

BioSURE Pro Protective Nasal Spray originated from the UK and contains the unique patented ingredient Ethyl Lauroyl Arginate Hydrochloride (ELAH), which has been clinically proven that block and inactivate over 99% of various respiratory viruses, including coronaviruses (including COVID-19), H1NI influenza, Human Respiratory (RSV) and rotaviruses.

With the approaching winter influenza season and the recent outbreak of respiratory viruses, if you’re tired of the discomfort caused by wearing surgical masks and want to reveal your appearance when going out, the Protective Nasal Spray is the ideal choice for you.

Purchase Locations

BioSURE Pro Protective Nasal Spray is currently available at Watson’s stores including the RX store, offline and online shop, HKTVmall, and DCH Auriga Store website.

Watsons RX Store: https://bit.ly/4136TEO
Watsons Online Store: https://bit.ly/49zgPtD
HKTVmall: https://bit.ly/3ZM3hGQ
DCH Auriga Store: https://bit.ly/3ZGjayr

About BioSURE

BioSURE originated in the UK and specializes in the research, development, manufacturing, procurement, and distribution of medical supplies. The company holds BSI certification, and its products are CE-marked, ensuring their safety and effectiveness for confident use.

Source : BioSURE Pro Protective Nasal Spray from the UK: Block airborne viruses instantly for six hours with a Gentle Lavender Scent

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network